The estimated Net Worth of Richard J Daly is at least 5.05 百万$ dollars as of 4 June 2024. Mr. Daly owns over 40,000 units of Catalyst Pharmaceuticals Inc stock worth over 4,906,781$ and over the last 9 years he sold CPRX stock worth over 0$. In addition, he makes 142,064$ as Independent Director at Catalyst Pharmaceuticals Inc.
Richard has made over 19 trades of the Catalyst Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of CPRX stock worth 160,400$ on 4 June 2024.
The largest trade he's ever made was exercising 60,000 units of Catalyst Pharmaceuticals Inc stock on 7 December 2023 worth over 67,800$. On average, Richard trades about 10,333 units every 72 days since 2015. As of 4 June 2024 he still owns at least 252,147 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Mr. Daly stock trades at the bottom of the page.
Richard J. Daly is Independent Director of Catalyst Pharmaceutical Partners, Inc. Mr. Daly currently serves as Chief Operating Officer of BeyondSpring Pharma, a pre-commercial company focused on cancer with assets in late Phase 3 trials. From 2016 until mid-2018, Mr. Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology. Until October 2014, Mr. Daly served as President of AstraZeneca US Diabetes, where he led all commercial and medical plans and objectives for a $1.2 billion, 3,000-employee division, including the successful launch of an orphan/rare disorder drug, Myalept, for Lipodystrophy. Mr. Daly currently serves on the board of directors of Opiant Pharmaceuticals, where he serves on the Compensation and Audit Committees of the board of directors. From June of 2015 to June 2018 Mr. Daly also served on the Board of Directors of Synergy Pharmaceuticals, where he chaired the Nominations/Corporate Governance Committee and was a member of the Compensation Committee. Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998. The Board believes that the characteristics that qualify Mr. Daly to be a director of our company include his significant pharmaceutical industry experience and his experience in launching and managing sales of numerous pharmaceutical products, including several products that are used to treat orphan/rare diseases.
As the Independent Director of Catalyst Pharmaceuticals Inc, the total compensation of Richard Daly at Catalyst Pharmaceuticals Inc is 142,064$. There are 13 executives at Catalyst Pharmaceuticals Inc getting paid more, with Patrick McEnany having the highest compensation of 3,371,560$.
Richard Daly is 59, he's been the Independent Director of Catalyst Pharmaceuticals Inc since 2015. There are 7 older and 8 younger executives at Catalyst Pharmaceuticals Inc. The oldest executive at Catalyst Pharmaceuticals Inc is Charles O'Keeffe, 80, who is the Lead Independent Director.
Richard's mailing address filed with the SEC is 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134.
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over 35,595,986$ worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth 7,307,159$ . The most active insiders traders include Pharmaceutical Inc Biomarin、Patrick J Mcenany、Steve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of 1,097,019$. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth 60,150$.
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: